The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the body or cannot be surgically removed.
On January 17, 2025, the Food and Drug Administration (FDA) approved datopotamab deruxtecan-dlnk a Trop-2-directed antibody ...
To treat your advanced HER2 ... growing cancer cells anywhere in your body. Chemotherapy may be given before surgery to shrink a large tumor or after to keep it from coming back. Some breast ...
The FDA approved datopotamab deruxtecan-dlnk for treatment of certain patients with advanced breast cancer.The indication ...
The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with ...
During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic ...
A new statistical tool that combines multiple clinical and pathologic factors with a patient's 21-gene Oncotype DX Breast ...
Adjuvant ado-trastuzumab emtansine significantly prolonged survival compared with trastuzumab for certain women with ...
The approval is based on findings from the phase 3, multicenter, open-label, randomized TROPION-Breast01 trial.
has compiled an impressive record as treatment for HER2-positive breast cancer. The agent outperformed T-DM1 in a randomized trial in HER2-positive metastatic breast cancer and demonstrated ...
Findings showed datopotamab deruxtecan reduced the risk of disease progression or death by 37% compared with chemotherapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback